Vilprafen Solutab, 1000 mg 10 pcs

Vilprafen solutab is bactericidal, bacteriostatic, antibacterial.

Pharmacodynamics

The drug is used to treat bacterial infections; the bacteriostatic activity of giosamycin, like other macrolides, is due to inhibition of bacterial protein synthesis. At high concentrations in the focus of inflammation it has a bactericidal effect.

Josamycin is highly active against intracellular microorganisms (Chlamydia trachomatis andChlamydia pneumoniae, Mycoplasma pneumoniae, Mycoplasma hominis, Ureaplasma urealyticum, Legionella pneumophila); Gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenesStreptococcus pneumoniae (pneumococcus), Corynebacterium diphtheriae), Gram-negative bacteria(Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Bordetella pertussis), as well as against some anaerobic bacteria (Peptococcus, Peptostreptococcus, Clostridium perfringens). Affects enterobacteria slightly, so it does not change the natural bacterial flora of the gastrointestinal tract. It is effective in resistance to erythromycin. Resistance to jozamycin develops less frequently than to other antibiotics of macrolide group.

Pharmacokinetics

After oral administration, giosamycin is quickly and completely absorbed from the gastrointestinal tract, food intake does not affect bioavailability. Cmax of giovamycin in serum is reached 1-2 hours after intake. About 15% of giovamycin is bound to plasma proteins. Particularly high concentrations of the substance are found in the lungs, tonsils, saliva, sweat and tear fluid. Concentration in sputum exceeds concentration in plasma by 8-9 times. It accumulates in bone tissue. It crosses the placental barrier and is secreted into breast milk. Josamycin is metabolized in the liver to less active metabolites and is excreted mainly with bile. Urinary excretion of the drug is less than 20%.

Indications

Acute and chronic infections caused by microorganisms sensitive to the drug, for example:

infections of the upper respiratory tract and ENT organs – tonsillitis, pharyngitis, paratonsillitis, laryngitis, otitis media, sinusitis, diphtheria (in addition to treatment with diphtheria toxoid), as well as scarlet fever in case of hypersensitivity to penicillin;
lower respiratory tract infections – acute bronchitis, exacerbation of chronic bronchitis, pneumonia (including those caused by atypical pathogens), whooping cough, psittacosis;
dental infections – gingivitis and periodontal disease;
infections in ophthalmology – blepharitis, dacryocystitis;
infections of the skin and soft tissues – pyoderma, furunculosis, anthrax, erysipelas (with hypersensitivity to penicillin), acne, lymphangitis, lymphadenitis, lymphogranuloma venereum;
infections of the genitourinary system – prostatitis, urethritis, gonorrhea, syphilis (with hypersensitivity to penicillin), chlamydial, mycoplasma (including ureaplasma) and mixed infections.

Pharmacological effect

Vilprafen solutab – bactericidal, bacteriostatic, antibacterial.

Pharmacodynamics

The drug is used to treat bacterial infections; The bacteriostatic activity of josamycin, like other macrolides, is due to inhibition of bacterial protein synthesis. When high concentrations are created at the site of inflammation, it has a bactericidal effect.

Josamycin is highly active against intracellular microorganisms (Chlamydia trachomatis and Chlamydia pneumoniae, Mycoplasma pneumoniae, Mycoplasma hominis, Ureaplasma urealyticum, Legionella pneumophila); gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae (pneumococcus), Corynebacterium diphtheriae), gram-negative bacteria (Neisseria meningitidis, Neisseria gonorrhoeae, Haemophilus influenzae, Bordetella pertussis), as well as against some anaerobic bacteria (Peptococcus, Peptostreptococcus, Clostridium perfringens). It has a slight effect on enterobacteria, and therefore little changes the natural bacterial flora of the gastrointestinal tract. Effective against resistance to erythromycin. Resistance to josamycin develops less frequently than to other macrolide antibiotics.

Pharmacokinetics

After oral administration, josamycin is quickly and completely absorbed from the gastrointestinal tract; food intake does not affect bioavailability. Cmax of josamycin in serum is achieved 1–2 hours after administration. About 15% of josamycin is bound to plasma proteins. Particularly high concentrations of the substance are found in the lungs, tonsils, saliva, sweat and tear fluid. The concentration in sputum is 8–9 times higher than the concentration in plasma. Accumulates in bone tissue. Crosses the placental barrier and is secreted into breast milk. Josamycin is metabolized in the liver to less active metabolites and excreted mainly in bile. Excretion of the drug in urine is less than 20%.

Special instructions

If one dose is missed, you should take a dose immediately, but if it is time for the next dose, you should return to your usual treatment regimen. You should not take double the dose. A break in treatment or premature discontinuation of the drug will reduce the likelihood of treatment success.

The possibility of cross-resistance to various macrolide antibiotics should be taken into account (for example, microorganisms that are resistant to treatment with antibiotics related in chemical structure may also be resistant to josamycin).

Active ingredient

Josamycin

Composition

Active ingredient:

josamycin 1000 mg (equivalent to josamycin propionate) – 1067.66 mg.

Excipients:

Microcrystalline cellulose – 564.53 mg;

hyprolose – 199.82 mg;

sodium docusate – 10.02 mg;

aspartame – 10.09 mg;

colloidal silicon dioxide – 2.91 mg;

strawberry flavoring – 50.05 mg;

magnesium stearate – 34.92 mg.

Pregnancy

Possibly according to indications.

It is the drug of choice for the treatment of chlamydial infection in pregnant women.

Contraindications

severe liver dysfunction;
children weighing less than 10 kg;
hypersensitivity to the components of the drug;
hypersensitivity to macrolide antibiotics.

Side Effects

From the gastrointestinal tract: rarely – loss of appetite, nausea, heartburn, vomiting, dysbacteriosis, diarrhea. In the case of persistent severe diarrhea, one should keep in mind the possibility of life-threatening pseudomembranous colitis developing against the background of antibiotics.

Allergic reactions: in extremely rare cases – urticaria.

From the hearing aid: in rare cases – dose-dependent transient hearing impairment.

Other: very rarely – candidiasis.

Interaction

Other antibiotics. Since bacteriostatic antibiotics can reduce the bactericidal effect of other antibiotics, such as penicillins and cephalosporins, co-administration of josamycin with these types of antibiotics should be avoided. Josamycin should not be prescribed together with lincomycin, because a mutual decrease in their effectiveness is possible.

Xanthines. Some representatives of macrolide antibiotics slow down the elimination of xanthines (theophylline), which can lead to possible intoxication. Clinical experimental studies indicate that josamycin has less effect on theophylline release than other macrolide antibiotics.

Antihistamines. After co-administration of josamycin and antihistamines containing terfenadine or astemizole, there may be a slowdown in the elimination of terfenadine and astemizole, which in turn can lead to the development of life-threatening cardiac arrhythmias.

Ergot alkaloids. There are individual reports of increased vasoconstriction following co-administration of ergot alkaloids and macrolide antibiotics. There was one case of patient’s lack of tolerance to ergotamine while taking josamycin. Therefore, the concomitant use of josamycin and ergotamine should be accompanied by appropriate monitoring of patients.

Cyclosporine. Co-administration of josamycin and cyclosporine may cause an increase in the level of cyclosporine in the blood plasma and the creation of nephrotoxic concentrations of cyclosporine in the blood. Plasma concentrations of cyclosporine should be regularly monitored.

Digoxin. When administered together, josamycin and digoxin may increase the level of the latter in the blood plasma.

Hormonal contraceptives. In rare cases, the contraceptive effect of hormonal contraceptives may be insufficient during treatment with macrolides. In this case, it is recommended to additionally use non-hormonal contraception.

Overdose

To date, there is no data on specific symptoms of poisoning.

In case of overdose, the symptoms described in the “Side Effects” section should be expected, especially from the gastrointestinal tract.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C

Shelf life

4 years

Manufacturer

ZiO-Zdorovye CJSC, Russia